IQVIA Named Top CRO in 2021 WCG CenterWatch Independent Survey
25 February 2022 - 12:00AM
Business Wire
IQVIA™ (NYSE:IQV), a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry was named the top CRO in Overall
Reputation by clinical trial sites around the world in the 2021 WCG
CenterWatch Global Site Relationship Benchmark Survey Report.
The results were based on responses from investigators, study
coordinators, nurses and others representing clinical trial sites
across North America, Europe, Asia and South America. Respondents
were asked to rank the overall reputation of 53 sponsors and 29
CROs they worked with the most in the previous two years and score
them across 35 performance-related attributes. According to
CenterWatch, survey respondents valued IQVIA’s comprehensive
decentralized trials, direct-to-patient recruitment and
therapeutic, clinical, regulatory, and technology expertise to meet
the individual and changing needs of sites and their patients.
The WCG CenterWatch Global Site Relationship Benchmark Survey is
an independent survey conducted biannually since 1997. The 2021
survey was deployed to more than 60,000 individuals between August
11 and September 22, 2021.
About IQVIA IQVIA (NYSE:IQV) is a leading global provider
of advanced analytics, technology solutions, and clinical research
services to the life sciences industry. IQVIA creates intelligent
connections across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 79,000 employees, IQVIA conducts operations n more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220224005364/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jul 2023 to Jul 2024